title: Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.
abstract: In this study, oritavancin had modal MIC, MIC50, and MIC90 values of 0.03, 0.03, and 0.06 μg/ml, respectively, against Staphylococcus aureus. Similar results (MIC50/90, 0.03/0.06 μg/ml) were observed against methicillin-resistant and -susceptible isolates and those demonstrating multidrug-resistant (MDR) and non-MDR phenotypes. When oritavancin (MIC50/90, 0.06/0.12 mg/ml) was tested against S. aureus with elevated MIC values for daptomycin (i.e., 1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC50/90, 0.03/0.06 mg/ml), yet it inhibited these isolates at ≤0.25 mg/ml.
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.forename: David J
authors.initials: DJ
authors.lastname: Farrell
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe; D006020:Glycopeptides / Q000494:pharmacology*; D006761:Hospitals; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*; D014481:United States; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin